As global markets react to anticipated interest rate cuts and small-cap stocks outperform their larger counterparts, the Hong Kong market presents intriguing opportunities for discerning investors. In this dynamic environment, identifying promising stocks involves looking for companies with robust fundamentals, strong growth potential, and resilience amid economic fluctuations.

Top 10 Undiscovered Gems With Strong Fundamentals In Hong Kong

Click here to see the full list of 178 stocks from our SEHK Undiscovered Gems With Strong Fundamentals screener.

Here's a peek at a few of the choices from the screener.

COSCO SHIPPING International (Hong Kong)

Simply Wall St Value Rating: ★★★★★★

Overview: COSCO SHIPPING International (Hong Kong) Co., Ltd., an investment holding company with a market cap of HK$6.44 billion, provides shipping services in the People’s Republic of China and internationally.

Operations: COSCO SHIPPING International (Hong Kong) generates revenue primarily from marine equipment and spare parts (HK$1.73 billion), coatings (HK$992.94 million), and general trading (HK$478.19 million). The company also earns from insurance brokerage (HK$175.51 million) and ship trading agency services (HK$99.97 million).

COSCO SHIPPING International (Hong Kong) reported earnings of HK$388.04 million for the half year ended June 30, 2024, up from HK$335.92 million a year ago. The company announced an interim dividend of HK$0.265 per share, reflecting its strong financial health and profitability. Earnings grew by 24.8% over the past year, outpacing the infrastructure industry's 9.3%. Debt-free for five years, it trades at a significant discount to its estimated fair value, making it an attractive investment prospect in Hong Kong's market.

• Get an in-depth perspective on COSCO SHIPPING International (Hong Kong)'s performance by reading our health report here.

• Gain insights into COSCO SHIPPING International (Hong Kong)'s past trends and performance with our Past report.

China Tobacco International (HK)

Simply Wall St Value Rating: ★★★★☆☆

Overview: China Tobacco International (HK) Company Limited engages in the tobacco business with a market cap of HK$10.87 billion.

Operations: The company generates revenue primarily from its Tobacco Leaf Products Import Business (HK$8.08 billion), followed by the Tobacco Leaf Products Export Business (HK$1.65 billion) and Cigarettes Export Business (HK$1.21 billion). The Brazil Operation Business and New Tobacco Products Export Business contribute HK$766.28 million and HK$129.98 million, respectively, to the overall revenue streams.

China Tobacco International (HK) reported half-year sales of HK$8.70 billion, up from HK$7.74 billion a year ago, with net income rising to HK$643 million from HK$457 million. Basic earnings per share increased to HK$0.93 compared to last year's HK$0.66. The company declared an interim dividend of HKD 0.15 per share for the six months ending June 2024, payable on September 27, 2024. Net debt to equity ratio stands at a high 70%.

• Delve into the full analysis health report here for a deeper understanding of China Tobacco International (HK).

• Review our historical performance report to gain insights into China Tobacco International (HK)'s's past performance.

YSB

Simply Wall St Value Rating: ★★★★☆☆

Overview: YSB Inc. develops a digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China and has a market cap of HK$4.79 billion.

Operations: YSB Inc. generates revenue primarily through its digital pharmaceutical platform, with a significant portion of costs attributed to technology development and operational expenses. The company's net profit margin has shown notable fluctuations, reflecting changes in both revenue streams and cost structures.

YSB Inc. recently reported half-year sales of CNY 8.81 billion, up from CNY 7.97 billion last year, while net income reached CNY 21.82 million compared to a net loss of CNY 3.17 billion previously. Basic earnings per share improved to CNY 0.03 from a loss per share of CNY 23.7 last year, reflecting significant turnaround efforts and profitability gains in the past year, making it challenging to compare with the broader healthcare industry’s growth rate of 8%.

• Unlock comprehensive insights into our analysis of YSB stock in this health report.

• Gain insights into YSB's historical performance by reviewing our past performance report.

Make It Happen

• Reveal the 178 hidden gems among our SEHK Undiscovered Gems With Strong Fundamentals screener with a single click here.

• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.

• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:517 SEHK:6055 and SEHK:9885.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]